Cytokinetics, Incorporated
CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin actā¦ read more
Healthcare
Biotechnology
21 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$60.06
Price+0.10%
$0.06
1Y
Price
Market Cap
$7.397b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-1015.8%
EBITDA Margin-1030.9%
Net Profit Margin-835.2%
Free Cash Flow Margin-1015.8%
EBITDA Margin-1030.9%
Net Profit Margin-835.2%
Free Cash Flow MarginRevenue
$88.039m
+376.6%
1y CAGR+143.3%
3y CAGR+116.0%
5y CAGREarnings
-$784.955m
-33.1%
1y CAGR-26.8%
3y CAGR-40.3%
5y CAGREPS
-$6.54
-24.1%
1y CAGR-15.5%
3y CAGR-25.3%
5y CAGRBook Value
-$659.625m
$1.425b
Assets$2.084b
Liabilities$1.284b
DebtDebt to Assets
90.2%
-1.8x
Debt to EBITDAFree Cash Flow
-$534.816m
-33.8%
1y CAGR-21.2%
3y CAGR-31.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company